New Patented Drugs

According to the patented medicine prices Guidelines, a drug product is "considered new in the year which [it is] introduced in Canada" and "for which the introductory price is under review:"

As a manufacturer introducing a new, patented medicine in Canada, you need to obtain the optimal price for your product for the desired return on your investment. Obtaining the optimal price requires proper planning and assessment of all opportunities and options and effectively presenting your case to the PMPRB.

For the most desired outcome, you can take advantage of Brogan Inc.'s proven expertise and experience. Our team has been working closely with the PMPRB for the past 15 years and can provide valuable advice; strategic assessments for pricing new patented drugs, and reliable forecasts of the allowable price early on, while the product is still in the pipeline.

For more information, please contact Brogan Inc. Price Regulation Consulting team at 613.599.0711 ext 255.